In The News
Stay informed with the latest research breakthroughs, treatment updates, and community stories related to Parkinson’s disease.
Once-daily treatment may reduce Parkinson’s off time, study finds
150 mg dose also improved on time without troublesome dyskinesia Written by Andrea Lobo | Oct. 13, 2026 Solengepras (CVN424) is an investigational oral treatment being studied for motor and non-motor Parkinson’s symptoms. The Phase 3 ARISE trial found 150 mg...
Parkinson’s drug shifts key biomarkers, trial results show
Arvinas' ARV-102 linked to improved eye movement control in Phase 1 study Written by Andrea Lobo | Oct. 14, 2026 ARV-102 successfully crossed the blood-brain barrier, reduced LRRK2 levels, and improved eye movement in a Phase 1 trial. The results build on earlier data...
FDA approves first-of-its-kind oral therapy for adults with Parkinson’s
New once-daily med Juvmo aims to maintain control of motor symptoms Written by Marisa Horak, MS | Sept. 29, 2026 The U.S. Food and Drug Administration has approved tavapadon, now known as Juvmo, to help better manage Parkinson's motor symptoms. The once-daily oral...
$3M federal grant will allow study of protein causing Parkinson’s dementia
Colorado State University team to target distinct variant of alpha-synuclein Written by Andrea Lobo | Oct. 1, 2026 A $3 million federal grant will fund new research into how a distinct variant of the alpha-synuclein protein contributes to Parkinson’s disease dementia....
Arm and hand exercises may ease tremor, improve grip in Parkinson’s
Benefits seen both alone and with virtual reality training in small trial Written by Patricia Inácio, PhD | Oct. 2, 2026 An eight-week program of arm and hand exercises was found to ease tremor and improve grip strength in people with Parkinson's. Adding virtual...
RBD tied to broader motor, psychiatric problems in Parkinson’s disease
Sleep disorder also linked to greater difficulty with everyday activities Written by Patricia Inácio, PhD | Oct. 5, 2026 REM sleep behavior disorder (RBD) in Parkinson’s disease was tied to a broader range of motor, psychiatric, and daily-function problems than...
DA Approves Tavapadon for the Treatment of Parkinson Disease
September 28, 2026 Author(s) Isabella Ciccone, MPH Key Takeaways Selective partial D1/D5 agonism aims to preserve motor efficacy while potentially avoiding D2/D3-mediated nonmotor tolerability liabilities, representing a mechanistically differentiated approach among...
Parkinson’s rehab program may sharpen thinking skills and lift mood
PD-CoRE improves memory, problem-solving, and depression in small study Written by Marisa Horak, MS | Sept. 29, 2026 Parkinson's disease often causes nonmotor symptoms such as cognitive decline, memory loss, impaired problem-solving, and depression. The PD-CoRE...
How Can Focused Ultrasound Treat Tremor and Movement Symptoms in Parkinson’s Disease?
Neurosurgery team performs first dual-target approach in the Rocky Mountain region 5 minute read by Chris Casey | September 15, 2026 The takeaway: Researchers and physicians at CU Anschutz performed the Rocky Mountain region’s first dual-target high-intensity focused...
Trial of experimental Parkinson’s vaccine shows positive initial results
ACI-7104 was generally safe, triggered an immune response against its target Written by Andrea Lobo | Sept. 28, 2026 The experimental vaccine ACI-7104 targets early Parkinson’s disease by aiming to reduce toxic alpha-synuclein clumps in the brain. Initial Phase 2...